49.500
-0.500
(-1.00%)
At close: January 28 at 11:50:25 AM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,582,421.730
7,825,190.298
10,255,325.393
4,638,834.178
3,149,689.676
Cost of Revenue
3,228,645.200
3,821,800.293
5,397,598.115
2,582,396.167
1,683,499.637
Gross Profit
2,353,776.530
4,003,390.005
4,857,727.278
2,056,438.011
1,466,190.039
Operating Expense
1,706,901.285
1,707,926.257
1,685,614.370
880,745.632
575,186.168
Operating Income
646,875.245
2,295,463.748
3,172,112.908
1,175,692.379
891,003.871
Net Non Operating Interest Income Expense
178,262.670
153,816.354
65,440.786
5,117.221
11,052.691
Pretax Income
828,162.596
2,557,129.702
3,724,944.188
1,192,949.373
814,356.218
Tax Provision
77,972.692
306,310.300
430,313.640
123,693.657
92,304.346
Net Income Common Stockholders
769,029.868
2,268,810.444
3,301,635.020
1,069,273.578
722,091.361
Basic EPS
2.17
6.26
9.02
3.15
2.21
Diluted EPS
2.17
6.26
9.00
3.13
2.20
Basic Average Shares
355,742.159
362,429.783
366,034.925
339,451.929
326,105.776
Diluted Average Shares
355,742.159
362,429.783
366,848.336
341,620.951
328,223.346
Total Operating Income as Reported
842,669.716
2,570,792.245
3,730,780.159
1,192,361.924
816,894.406
Rent Expense Supplemental
--
1,072.753
--
2,732.215
2,859.545
Total Expenses
4,935,546.484
5,529,726.550
7,083,212.485
3,463,141.798
2,258,685.804
Net Income from Continuing & Discontinued Operation
769,029.868
2,268,810.444
3,301,635.020
1,069,273.578
722,091.361
Normalized Income
799,549.109
2,278,201.739
3,254,207.641
1,072,326.996
740,200.128
Interest Income
222,833.626
160,138.114
76,624.943
12,992.124
15,111.122
Interest Expense
8,365.022
5,911.681
10,529.441
7,328.337
2,502.342
Net Interest Income
178,262.670
153,816.354
65,440.786
5,117.221
11,052.691
EBIT
836,527.618
2,563,041.383
3,735,473.629
1,200,277.710
816,858.559
EBITDA
836,527.618
3,026,983.844
4,077,210.008
1,414,605.948
973,687.328
Reconciled Cost of Revenue
3,228,645.200
3,821,800.293
5,397,598.115
2,582,396.167
1,683,499.637
Reconciled Depreciation
--
463,942.461
341,736.379
214,328.238
156,828.769
Net Income from Continuing Operation Net Minority Interest
769,029.868
2,268,810.444
3,301,635.020
1,069,273.578
722,091.361
Total Unusual Items Excluding Goodwill
-33,691.328
-10,669.340
53,621.897
-3,406.644
-20,423.722
Total Unusual Items
-33,691.328
-10,669.340
53,621.897
-3,406.644
-20,423.722
Normalized EBITDA
870,218.946
3,037,653.184
4,023,588.111
1,418,012.592
994,111.051
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-3,172.087
-1,278.046
6,194.518
-353.226
-2,314.955
12/31/2020 - 12/10/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
688202.SS Shanghai Medicilon Inc.
27.49
-1.82%
2171.HK CARsgen Therapeutics Holdings Limited
10.080
-2.51%
6826.HK Shanghai Haohai Biological Technology Co., Ltd.
24.800
-2.75%
6660.HK AIM Vaccine Co., Ltd.
5.800
-1.19%
2157.HK Lepu Biopharma Co., Ltd.
2.730
-4.88%
2197.HK Clover Biopharmaceuticals, Ltd.
0.218
-0.91%
2257.HK Sirnaomics Ltd.
2.890
+4.33%
3759.HK Pharmaron Beijing Co., Ltd.
14.100
-1.40%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
159.300
-0.62%
1952.HK Everest Medicines Limited
40.300
-0.86%